Key facts
- This page summarizes Joseph E. Gilliam's Form 3 filing for Caris Life Sciences, Inc..
- 0 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2025, 21:34.
Joseph E. Gilliam - 17 Jun 2025 Form 3 Insider Report for Caris Life Sciences, Inc.
- Reporting relationship
- Director
- Issuer ticker
- CAI on Nasdaq
- Reported as of
- 17 Jun 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 17 Jun 2025, 21:34:52 UTC
- Prior SEC filing
- 30 May 2025
- Next SEC filing
- 22 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ J. Russel Denton, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Joseph E. Gilliam filed Form 3 for Caris Life Sciences, Inc. on 17 Jun 2025.
Change
- Previous filing in this sequence was filed on 30 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0001705850
Primary reporting owner
Gilliam Joseph E
- Relationship
- Director
- Address
- C/O CARIS LIFE SCIENCES, INC., 750 W. JOHN CARPENTER FREEWAY, SUITE 800, IRVING
- Signature
- /s/ J. Russel Denton, Attorney-in-Fact
- Signature date
- 17 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CAI
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 16,129
- Date
- 17 Jun 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CAI
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 75,000
- Exercise price
- $8.00
- Footnotes
- F2
CAI
holding
Derivative
Stock Option
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 17 Jun 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,500
- Exercise price
- $18.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Includes 16,129 shares of Common Stock underlying restricted stock units which vest in accordance with the applicable grant agreement.
Footnote F2
The stock option is fully vested and exercisable.
SEC remarks
Exhibit 24 - Power of Attorney.